










doi:10.101Targeting Treg Cells In Situ: Emerging Expansion
Strategies for (CD41CD251) Regulatory T Cells
Alwi Shatry, Jackeline Chirinos, Michael A. Gorin, Monica Jones, Robert B. Levy1 1Recognition of the ability of CD4 FoxP3 T cells (Treg) to influence the generation of peripheral immune
responses has engendered enthusiasm for the development of strategies utilizing these cells to regulate
immune responses in clinically important settings including transplantation, autoimmunity and cancer. A
number of studies have reported effective regulation utilizing ex-vivo expansion approaches and subsequent
transfer of Treg populations in experimental models. This commentary discusses recently emerging
strategies to activate and expand Treg cells in situ which include antibodies, antigen presenting cells and
the use of IL2 / anti-IL2 antibody complex. The development of reagents which can stimulate and / or remove
Treg cells in situwould represent an important advance towards facilitating new opportunities to harness this
compartment for the augmentation of ‘wanted’ or suppression of ‘unwanted’ immune responses. Simulta-
neous targeting of multiple molecules on Treg cells may ultimately enable more effective control of this
regulatory sector.
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Marrow allograft resistanceCD41FoxP31 regulatory T cells play an impor-
tant regulatory mission with regard to the generation
of peripheral immune responses. Recognition of this
involvement has engendered enthusiasm for the devel-
opment of new strategies to attempt to influence
immune responses in clinically important settings. In
the case of cancer or viral insult, diminution of Treg
numbers and/or blocking their function provide prom-
ising approaches to enhance antitumor/pathogen
immunity. Alternatively, augmenting Treg numbers
and/or function is now envisioned as a potential strat-
egy to downregulate autoimmune responses and to
facilitate the establishment of tolerance to allogeneic
transplantation antigens. Key elements for any such
proposed strategies are reagents that can have an effec-
tive impact on the Treg compartment. Theoretically,
manipulating Treg cells in vitro as well as in vivo
would elevate the likelihood of clinical success depen-
dent on the intended purpose. Approaches to activateDepartment of Microbiology and Immunology, Univer-
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vivo are now well established. Most involve the use
of anti-CD3 monoclonal antibody (mAb) plus anti-
CD28 costimulation together with IL-2, and more
recently rapamycin, has shown the capacity to further
select for Treg cell expansion [1-6]. Both animal as
well as human Treg cell cultures generally respond
to these types of protocols, and although there has
been significant variation in the overall expansion
reported, the general consensus is that over a 1- to
2-week time interval, several hundredfold increases
in recovery following anti-CD3/CD281 IL-2 is not
unreasonable [1,7,8]. In addition to direct antibody
‘‘targeting’’ of Treg cells in vitro, the use of allogeneic
APC populations has also been reported to expand
Treg numbers ex vivo, and following in vivo adminis-
tration, these Tregs expressed functional activity
including tolerance induction [9-11]. Interestingly,
rapamycin treatment of myeloid-derived DC-dimin-
ished major histocompatibility complex (MHC) class
II and B7 expression, resulting in poor allogeneic
Tconv stimulation while enriching for functional
Treg cells [5]. A fundamental issue beginning to be un-
derstood, is the precise nature of the ex vivo expanded
Treg cells, including their overall functional capabil-
ities. To date, there have been few studies carefully
assessing the relative regulatory capacity of in vitro
expanded versus fresh in vivo populations in individual
well-defined models. One study reported that anti-




















































Figure 1. Model of IAC-induced suppression of HVG Tconv cells and facilitation of chimerism post-allogeneic hematopoietic stem cell transplantation
(HSCT). Following conditioning, residual host Treg cells can be activated and expanded in situ by IL2/anti-L2 complex (IAC). Aworking hypothesis for the
regulation of HVG and facilitation of engraftment is the subsequent engagement of host Treg cells and host Tconv cells at the donor APC interface.
Inhibition of resistance against the donor graft might proceed via direct (Treg-Tconv) and/or indirect (Treg-donor APC) pathways. The effector
molecules that mediate the regulation are unknown.
1240 Biol Blood Marrow Transplant 15:1239-1243, 2009A. Shatry et al.TCR transgenic Treg cells enhanced their functional
in vivo activity, whereas another using anti-CD3/
CD28 mAb beads examining polyclonally activated
allogeneic Tregs in a graft-versus-host disease
(GVHD) model reported that greater numbers of in
vitro expanded versus fresh Tregs were needed to
induce comparable levels of suppression [12,13]. The
winged-helix family transcription factor FoxP3 is not
only a marker for Treg cells, but is also important in
programming the regulatory function of these cells
[14,15]. Some studies have reported a decrease in the
level of FoxP3 expression following in vitro expansion
of several Treg populations, which may reflect
epigenetic regulation [16-18]. Thus, the decreased
functional capacity exhibited by some ex vivo
expanded Treg cells could reflect their diminished
FoxP3 levels.
In addition to in vitro manipulation of Treg cells,
control of these cells in situ remains a major objective
of the field. In situ reduction strategies are potentially
powerful, and several approaches aimed at deleting
Tregs have shown at least partial success. For example,
the administration of anti-IL2RAbs and the infusion of
IL2-DPT (ie, diftitoxin) have induced significant
diminishment of human and murine peripheral Treg
levels [19-23]. However, because these reagents target
surface CD25 expression, such approaches can only
ablate the CD41FoxP31 compartment in the rangeof 50% to 70%, as CD252FoxP31 cells cannot be
deleted using these strategies. Consequently, the re-
mainder of the Treg compartment, together with the
rapid rebound of the nondeleted regulatory cells to
normal Treg levels (several days), complicates inter-
pretation in these types of studies [24].
In contrast to in situ Treg deletion, Lin and Hunig
[25] first reported the ability to expandTregs in vivo by
targeting CD28 in rats. Using a superagonistic anti-
CD28 ab, Treg cells were found to be preferentially
expanded over other T cell subsets, on the order of
a 20 increase of lymph node Tregs within 3 days of
infusion [25]. Use of a murine anti-CD28 mAb in an
allogeneic BMT model resulted in increased numbers
of donor Tregs in recipient lymph nodes associated
with protection from acute GVHD (aGVHD) [26]. A
number of groups have used DC-based protocols to
expand alloantigen and conventional antigen reactive
Treg cells in situ, increasing enthusiasm toward regu-
lating transplantation responses [5,10,27]. Interest-
ingly, not only have rapamycin-treated DC shown
promise in this regard, but RAPA itself has also been
found to promote expansion of FoxP3 Tregs, which,
in the context of allogeneic transplants, may promote
transplant antigen specificTregs [28]. Still other proto-
cols including anti-CTLA4 ab treatment blockade and
the infusion of i.v. immunoglobulin have also report-

























































Figure 2. Potential strategies for manipulation of Treg cells following IAC or antigen- induced activation by targeting upregulated cell surfacemolecules.
Treg cells can be activated and expanded following experimental treatment with IAC (IL2/anti-IL2 complex) or via responsiveness to auto (self), allo-
geneic (transplant), or conventional (pathogen) antigens. Following activation, upregulation of cell surface molecules including CD25 and TNFR family
members may provide ‘‘targets’’ for additional manipulation of different Treg populations. 4-1BB (TNFRS9), Ox-40 (TNFRS4), and GITR (TNFRS18)
reported to affect Treg function are shown, but other TNF family molecules as well as molecules yet to be identified could become potential targets
for manipulation.
Biol Blood Marrow Transplant 15:1239-1243, 2009 1241Targeting Treg Cells In SituMore recently, the use of IL-2-based strategies has
generated further enthusiasm for in vivo strategies to fa-
cilitate Treg expansion. Boyman and colleagues [32] re-
ported that the infusion of anti-IL-2/IL-2 cytokine
complexes can stimulate rapid and large-scale expansion
of CD41CD251 T cells in situ. A single anti-IL2 mAb
clone (JES6-1A12) complexed to IL-2 was found to ef-
fectively target and expand CD41CD251 T cells in
vivo [32,33].
We have found that within a few days following the
final infusion of such complexes, Treg levels rapidly
return to normal, further highlighting the stringent
physiologic regulation of this compartment [34,35].
The ability to augment Treg cell numbers in situ is
clearly attractive from the perspective of transplanta-
tion tolerance induction. Studies from our laboratory
have recently employed (Fig. 1) complex administra-
tion (IL2/anti-IL-2 complex [IAC]) to manipulate
endogenous Treg cells in recipients following MHC-
matched allogeneic hematopoietic progenitor cell
transplants [34]. Interestingly, IAC infusion was found
to target residual host Treg cells remaining following
sublethal TBI conditioning [35], resulting in their
rapid and marked expansion within the first 7 to 10
days posttransplant (Fig. 1). Examination of the host-
versus-graft (HVG) response in these reduced-
intensity conditioned (RIC) recipients (Fig. 1)demonstrated that such immunity was efficiently
blocked by this IAC infusion, which was accompanied
by the rapid and efficient engraftment of allogeneic T
cell-depleted marrow grafts [34]. Thus, with respect to
BMT, these observations suggested that (1) following
RIC and BMT, surviving host Tregs present can be
stimulated and expanded by infusion of these com-
plexes and retain in vitro suppressive function (M.
Gorin., A. Shatry, and R. Levy, unpublished), and (2)
in situ manipulation of Treg cells is a viable approach
to regulate allo-immunity post-transplant (Fig. 1).
An important benefit of such an in vivo approach is
the circumvention of the need to isolate, expand, and
harvest Treg cells from cultures prior to their applica-
tion in the transplant setting. A number of additional
manipulations in recipients can be envisioned to
strengthen such Treg-mediated regulation and
facilitate engraftment with the objective of alloantigen
tolerance induction. For example, in vitro and in vivo
studies have observed that in the presence of costimu-
latory signal blockade, Treg cells appear to retain their
functional capacity [36,37]. Thus, interfering with
costimulatory signals between donor APC and host
T cells (eg, use of rapamycin, CTLA-4 blockade,
etc.) to further ‘‘weaken’’ allo-responsiveness post-
transplant combined with expanding the Treg com-
partment may provide a heightened and more potent
1242 Biol Blood Marrow Transplant 15:1239-1243, 2009A. Shatry et al.suppressive environment for hematopoietic engraft-
ment and tolerance induction. It is tempting to
consider that although polyclonal expansion of Tregs
with IAC likely ensues in our transplant model, admin-
istration of IAC following alloantigen (ie, post-BMT)
infusion may also result in the expansion of Treg cells
with allo-specific TCR. Although we do not as yet
know if such Tregs are generated by this protocol, an
increase in Treg cells with antidonor antigen specific-
ity could further strengthen their ability to inhibit con-
ventional host T cells responding to donor alloantigen
via direct antigen stimulation on donor APC following
transplant. Notably, the administration of cytokine/
antibody complexes in nontransplant settings is also
being examined. A recent study reported that the infu-
sion of IL2/anti-IL2 complexes both prior to airway
challenge or therapeutically following airway inflam-
mation augmented FoxP31 as well as other regulatory
T cell (ie, TR1) populations, and resulted in significant
reduction in airway pathology in an experimental
airway allergy model [38]. Finally, an intriguing obser-
vation following 2 to 3 IAC infusions was the finding
that CD25 levels were markedly enhanced on
CD41CD251 T cells with minimal alteration of
FoxP3 levels, which contrasts the reported diminution
in some in vitro systems noted above [34]. What is
presently unknown, however, is whether sustained in
vivo IAC administration may lead to prolonged activa-
tion/expansion of Tregs and any downregulation of
their FoxP3 expression and functional capability.
The elevation of high affinity IL-2R expression thus
provides a potential target for cytokine, that is, IL-2
driven stimulation and the in situ expansion of Tregs.
Indeed, the addition of IL-2 in vitro to IAC-stimulated
Tregs resulted in driving high levels of proliferation
compared to freshly isolated Tregs from non-IAC-
treated animals [34]. Such observations suggest that
infusion of relatively low amounts of IL-2 in vivo
following even a single pulse of IAC may be capable
of driving and maintaining Treg expansion, for
example, during the initial phases of alloreactivity,
thus providing an alternative to multiple complex in-
jections. Interestingly, several investigations have
demonstrated the capacity of IL-2 to expand human
Tregs in vivo in cancer, autoimmune, and lympho-
penic environments and an intriguing recent study
noted that low dose IL-2 infusions can expand FoxP31
Treg cells in allogeneic HCT recipients of donor
CD41 T cell infusions [39-43]. Thus, we speculate
that in situ activation of Tregs under these conditions
could conceivably enhance their responsiveness to
low-dose IL-2.
It is interesting to speculate that once Tregs have
become activated, other molecules may be capable of
providing ‘‘targets’’ to expand and regulate the func-
tioning of these cells Fig. 2. For example, the upregu-
lation of 41BB expression on Tregs in response to IL-2enabled their effective in vitro expansion with a soluble
4-1BBL reagent [44]. Recent studies examining Treg
cells following allogeneic HCT proposed that IL-4
produced by natural killer T (NKT) cells was respon-
sible for expanding donor Treg cells in vivo posttrans-
plant, and seminal plasma has been proposed to be
associated with expansion of the CD41CD251 Treg
pool contributing to maternal immune tolerance dur-
ing pregnancy [45,46]. Clearly, the development of
reagents that can target and stimulate Treg cells in
situ will provide additional opportunities to harness
this compartment for the augmentation of ‘‘wanted’’
or suppression of ‘‘unwanted’’ immune responses.ACKNOWLEDGMENTS
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